BioCentury
ARTICLE | Clinical News

CHS-1701: Phase I data

July 18, 2016 7:00 AM UTC

Top-line data from a single-blind, crossover, U.S. Phase I trial in 122 healthy volunteers showed that a single dose of 6 mg subcutaneous CHS-1701 met the co-primary endpoints of pharmacokinetic and p...